Ziftomenib

Menin Inhibitor

Key facts

Ziftomenib is an onp drug in the Menin Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2025. Its mechanism of action is classified as Menin Inhibitors. DrugCentral lists 1 molecular target, including MEN1. Recorded indications include Acute myeloid leukemia with a susceptible NPM1 mutation.

• Approval status: onp (first approved 2025 by the FDA).
• Drug class: Menin Inhibitor.
• Mechanism of action: Menin Inhibitors.
• Molecular targets: MEN1 (1 listed in DrugCentral).
• Indications: Acute myeloid leukemia with a susceptible NPM1 mutation.
• Molecular formula: C33H42F3N9O2S2; molecular weight 717.89 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Acute myeloid leukemia with a susceptible NPM1 mutation

Mechanism & targets

• Mechanism of action (MoA): Menin Inhibitors
• Established pharmacologic class: Menin Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
Menin	MEN1	inhibitor	IC50 7.43

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2025-11-13	FDA	—	Kura Oncology	Yes

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: NPM1 · Testing Required

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Ziftomenib is on its molecule page.

• Molecular formula: C₃₃H₄₂F₃N₉O₂S₂
• Molecular weight: 717.89 g/mol
• CAS number: —
• InChIKey: BGGALFIXXQOTPY-NRFANRHFSA-N
• PubChem CID: 138497449

CC1=C(C=CC2=C1C=C(N2C[C@H](C)N3CCN(CC3)S(=O)(=O)C)C#N)CN4CCC(CC4)NC5=C6C=C(SC6=NC(=N5)NC)CC(F)(F)F

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ziftomenib used for?

DrugCentral lists the following indications for Ziftomenib: Acute myeloid leukemia with a susceptible NPM1 mutation.

How does Ziftomenib work?

Ziftomenib is classified as Menin Inhibitors; its molecular targets in DrugCentral include MEN1 (inhibitor).

When was Ziftomenib first approved?

Ziftomenib was first approved by the FDA in 2025.

What drug class does Ziftomenib belong to?

Ziftomenib is in the Menin Inhibitor class.

What is the chemical formula of Ziftomenib?

Ziftomenib has the molecular formula C33H42F3N9O2S2 and a molecular weight of 717.89 g/mol.

Sources

• DrugCentral drug card 5788 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL5095038 — compound record and bioactivity
• PubChem CID 138497449 — chemical identifiers
• DrugBank DB17171 — drug record
• FDA UNII 4MOD1F4ENC — substance identity
• DailyMed: FDA labels for Ziftomenib — current prescribing information (label search)
• UniProt O00255 (MEN1) — target protein
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.